Isodiol to begin marketing new line of phytoceutical products for kathy ireland® Health & Wellness and Ireland Men One
January 8, 2018 – Vancouver, BC – Isodiol International Inc., (CSE: ISOL) (OTC:ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global bioactive phytoceutical innovator specializing in the development of pharmaceutical and wellness products, announced today that it has entered into a licensing agreement with Level Brands Inc. (NYSE: LEVB), an innovative marketing and licensing company that provides bold, unconventional and socially responsible branding for leading businesses.
Under the agreement, Isodiol will work with Level Brands to develop consumer products for its subsidiaries, kathy ireland® Health & Wellness and Ireland Men One (I’M1), the company’s lifestyle brand for men. Encore Endeavor One (EE1), Level Brands’ corporate brand management and producer of experiential entertainment events, will provide strategic advisory services for the new wellness product lines.
“We look forward to incorporating Kathy Ireland’s proven genius into Isodiol’s existing product strategy,” says Marcos Agramont, CEO of Isodiol. “With more than 17,000 diverse offerings in the product line, Kathy Ireland has earned the confidence of millions and we are excited to introduce those consumers to the Isodiol brand. She will bring tremendous energy into this burgeoning field and we look forward to working with her and the Level Brands’ team to provide safe, consistent, and highly bioactive cannabinoid products to the ever-expanding market.”
kathy ireland® Health & Wellness, I’M1 and EE1 are led in marketing and creative by Stephen Roseberry, President and Chief Marketing Officer of kathy ireland® Worldwide (kiWW®), together with kiWW®’s Global Creative Director, Jon Carrasco.
“Level Brands is committed to exploring cutting-edge technologies and products and bringing them to the American market,” says Martin A. Sumichrast, CEO of Level Brands’. “Isodiol is a pioneer and a leader in the commercialization of a 99%+ pure, bioactive pharmaceutical grade cannabinoid products derived from the hemp plant. We are excited to work with Isodiol on developing the highest quality hemp derivatives-based consumable and topical skin care products for our kathy ireland® Health & Wellness and I’M1 brands.”
The new Isodiol kathy ireland® Health & Wellness and I’M1 products will debut in the Spring of 2018 and will be available through online and select distribution channels. Level Brands is committed to social responsibility, with each partner, client, and licensee supporting its Millennium Development Goals to improve the condition of lives around the world. Additional information around these initiatives will be provided in the near future.
Level Brands will receive an initial $2,000,000 USD payment in the form of Isodiol shares subject to 30-month escrow, $125,000 in cash over 6 months, $750,000 USD per quarter in the form of Isodiol shares subject to 30-month escrow and a 3% royalty on all gross sales of branded products. The contract term is for an initial 5 years and the both companies expect to conclude arrangements no later than January 31st.
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
About Level Brands, Inc.
Level Brands creates bold, unconventional and socially responsible branding for leading businesses. With a focus on corporate brand management and consumer products marketing art, beauty, fashion, health & wellness including the beverage space, entertainment, and real estate. Licensed brand marketing is at the core of the Level Brand businesses: Ireland Men One or I’M1, for millennial men and the women who love them; Encore Endeavor One or EE1, corporate brand management and producer of experiential entertainment events and products across multiple platforms; kathy ireland® Health & Wellness; Beauty & Pin-Ups, Level Brands’ hair care and disruptive women’s products brand.
ON BEHALF OF THE BOARD
“Marcos Agramont” CEO & Director
COMPANY MEDIA :
North 6th Agency
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.